Rare Disease And Neurology Of Particular Interest To New €300m VC Fund
This article was originally published in Scrip
Executive Summary
European venture capital firm Sofinnova Partners has closed its Sofinnova Capital VIII fund at €300m, €50m above its initial fund target. Rafaèle Tordjman, managing partner, told Scrip the money would be used to fund around 15 new companies.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.